Combinations for the treatment of non-tuberculosis mycobacterial diseases

The combination therapy of bedaquiline, macrolides and ethambutol has solved the problems of high side effects and failure rate in existing treatments for nontuberculous mycobacterial lung diseases, and provides a more effective and safer treatment option, especially for patients with refractory NTM-PD, shortening the treatment cycle.

CN122320982APending Publication Date: 2026-07-03JANSSEN PHARMA NV
View PDF 4 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
JANSSEN PHARMA NV
Filing Date
2020-01-08
Publication Date
2026-07-03

AI Technical Summary

Technical Problem

Current treatments for nontuberculous mycobacterial (NTM) lung diseases have significant side effects and high failure rates, and there is a lack of effective alternative treatment options, especially for patients with multidrug-resistant MAC-PD, where the treatment cycle is long and the results are poor.

Method used

Combination therapy using bedaquiline, macrolides (such as clarithromycin or azithromycin), and ethambutol, with the addition of injectable aminoglycosides as needed, can be administered together or separately at different time intervals to enhance efficacy.

Benefits of technology

It improves the treatment efficacy against nontuberculous mycobacteria, reduces side effects, and provides a more effective and safer treatment option, especially for patients with refractory NTM-PD, shortening the treatment cycle.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

This invention relates to combinations for treating nontuberculous mycobacterial diseases. Specifically, it relates to combinations of bedaquiline, macrolides (e.g., clarithromycin), and optionally ethambutol for use in the treatment of diseases associated with nontuberculous mycobacteria (NTM).
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Quinoline derivatives and their use as mycobacterial inhibitors

    WO2004011436A1

  • Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases

    WO2005117875A1

  • Quinoline derivatives for the treatment of latent tuberculosis

    WO2006067048A1

  • Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

    WO2008068231A1